



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-S protein [P17] Standard Size Ab03449-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: P17

Alternative Name(s) of Target: Spike glycoprotein; Receptor Binding Domain; SARS CoV 2 S glycoprotein; COVID-19 Spike protein; RBD; Receptor Binding Domain; S glycoprotein; SARS coronavirus 2 S protein; SARS coronavirus 2 Spike Protein; SARS CoV 2 Spike protein; SARS CoV 2; SARS-CoV-2 S protein; SARSCoV2; SARS-COV-2 S protein; SARS-COV-2 Spike glycoprotein; SARSCOV2 Spike protein; Severe acute respiratory syndrome 2 spike glycoprotein; Severe acute respiratory syndrome virus 2 spike glycoprotein; S glycoprotein; E2; Peplomer protein

UniProt Accession Number of Target Protein: P0DTC2

Published Application(s): in vivo, neutralizing, SPR, ELISA, IF

Published Species Reactivity: SARS-CoV-2

Immunogen: The original antibody was generated in the screening studies by using recombinant RBD of SARS-CoV-2 as a target against a fully human naive antibody library.

Specificity: The antibody binds the Spike protein of the SARS-CoV-2. The antibody does not crossreact with SARS-CoV RBD.

Application Notes: The specificity of the antibody was confirmed by ELISA analysis ($EC_{50} = 29 \text{ pM}$). Surface plasmon resonance (SPR) assays demonstrated that the antibody bound to SARS-CoV-2 RBD with a high affinity of 96 pM. Immunofluorescence staining showed that the antibody prevented SARS-CoV-2 infection in a dosedependent manner in Vero cells. Pseudovirus neutralization assay (PSV) in Huh7 cells and standard 50% plaque reduction neutralization tests (PRNT) in Vero cells, both showed that the antibody exhibited stronger neutralizing activity with IC_{50} and PRNT50 values of 165 and 195 pM, respectively. The antibody conferred effective protection in animal models. The structure of the Fab fragment and a prefusion stabilized SARSCoV-2 S ectodomain trimer was characterized using single-particle cryo-EM. The antibody was employed together with H014 to develop a therapeutic antibody cocktail against SARS-CoV-2 with neutralizing properties (Yao et al., 2021; PMID: 33262452).

Antibody First Published in: Yao et al. Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection. Cell Res. 2021 Jan;31(1):25-36. PMID:33262452

Note on publication: The original paper describes the development of a human antibody cocktail.

Product Form

Size: 200 µg Purified antibody.

Purification: Protein A affinity purified

Supplied In: PBS with 0.02% Proclin 300.

Storage Recommendation: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.